Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
10.25
+0.68 (7.11%)
At close: Jun 26, 2026, 4:00 PM EDT
10.20
-0.05 (-0.49%)
After-hours: Jun 26, 2026, 7:52 PM EDT

Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.

It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.

It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats.

In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization.

The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 485
CEO Jason Kelly

Contact Details

Address:
27 Drydock Avenue, 8th Floor
Boston, Massachusetts 02210
United States
Phone 877 422 5362
Website ginkgo.bio

Stock Details

Ticker Symbol DNA
Exchange NYSE
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001830214
CUSIP Number 37611X209
ISIN Number US37611X2099
Employer ID 87-2652913
SIC Code 2836

Key Executives

Name Position
Dr. Jason Kelly Ph.D. Co-Founder, Co-Chief Operating Officer, Chief Executive Officer and Director
Dr. Reshma P. Shetty Co-Founder, President and Director
Steven P. Coen CPA Chief Financial Officer
Thomas Knight Jr. Founder
Austin Che Ph.D. Co-Founder and Head of Strategy
Bartholomew Canton Ph.D. Co-Founder and Chief Technology Officer
Jennifer Wipf Co-Chief Operating Officer
Karen Tepichin General Counsel and Secretary
Daniel Marshall Senior Manager of Communications and Ownership
Brian O'sullivan Head of Commercial

Latest SEC Filings

Date Type Title
Jun 12, 2026 8-K Current Report
Jun 10, 2026 144 Filing
May 22, 2026 144 Filing
May 15, 2026 SCHEDULE 13G/A Filing
May 13, 2026 144 Filing
May 7, 2026 10-Q Quarterly Report
May 7, 2026 8-K Current Report
Apr 29, 2026 ARS Filing
Apr 29, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2026 DEF 14A Other definitive proxy statements